Oxaliplatin and 5-FU Based Preoperative Chemoradiation

Conditions

Rectal Cancer

Keywords

Oxaliplatin, radiation

Brief summary

Oxaliplatin and 5FU based preoperative chemoradiation in rectal cancer.

Detailed description

Effect of treatment, safety profile and quality of life scorings.

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR.

2019-05-2741 citations

10.1016/j.tranon.2019.04.014

High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer

Hanna Abrahamsson, Alina Carmen Porojnicu, Jonas Christoffer Lindstrøm, Svein Dueland, Kjersti Flatmark et al. (11 authors)

BMC Cancer2019-05-2313 citations

10.1186/s12885-019-5724-z

Circulating vitamin D during neoadjuvant therapy in high-risk rectal cancer.

Hanna Abrahamsson, Alina Carmen Porojnicu, Jonas Christoffer Lindstrøm, Svein Dueland, Kjersti Flatmark et al. (11 authors)

Journal of Clinical Oncology2018-05-20

10.1200/jco.2018.36.15_suppl.e15532

Abstract 1782: Reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) damage in tumor hypoxia, poor radiotherapy response, and metastatic progression of rectal cancer

Paula A. Bousquet, Sebastian Meltzer, Linda Sønstevold, Ying Esbensen, Lars Gustav Lyckander et al. (10 authors)

Cancer Research2017-07-013 citations

10.1158/1538-7445.am2017-1782

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH.

2016-07-264 citations

10.1186/s12885-016-2601-x

Abstract 4006: Oxaliplatin-induced immune factors and long-term disease control in rectal cancer - a reflection of immunogenic tumor cell death

Sebastian Meltzer, Erta Kalanxhi, Svein Dueland, Kjersti Flatmark, Kathrine Røe Redalen et al. (6 authors)

Cancer Research2016-07-151 citations

10.1158/1538-7445.am2016-4006

Abstract C101: Circulating tumor necrosis factor receptor (TNFR) proteins in systemic disease outcome to combined-modality radiotherapy in rectal cancer

Sebastian Meltzer, Erta Kalanxhi, Helga Helseth Hektoen, Svein Dueland, Kjersti Flatmark et al. (7 authors)

Molecular Cancer Therapeutics2015-12-01

10.1158/1535-7163.targ-15-c101

Abstract 571: Circulating proteins in response to combined-modality therapy in locally advanced rectal cancer identified by antibody array screening

Erta Kalanxhi, Helga Helseth Hektoen, Sebastian Meltzer, Svein Dueland, Kathrine Røe Redalen et al. (7 authors)

Cancer Research2015-08-01

10.1158/1538-7445.am2015-571

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH.

2015-07-2414 citations

10.1186/s12885-015-1557-6

Abstract B29: High tumor PI3K signaling in resistance to chemoradiotherapy and metastatic dissemination of locally advanced rectal cancer

Anne Hansen Ree, Kjersti Flatmark, Marie Grøn Sælen, Sigurd Folkvord, Svein Dueland et al. (7 authors)

Molecular Cancer Therapeutics2015-07-01

10.1158/1538-8514.pi3k14-b29

Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies.

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR.

2015-01-1215 citations

10.1016/j.critrevonc.2015.01.003

Interventions

DRUGOxaliplatin

DRUGChemoradiation

DRUG5-FU

RADIATIONPreoperative chemoradiation

PROCEDUREPelvic surgery

DRUGNeoadjuvant oxaliplatin

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

Rectal cancer

Design outcomes

Primary

Measure	Time frame
Safety profile	5 years
Number of patients obtaining pCR	5 years

Secondary

Measure	Time frame
Clinical, radiological and molecular response to treatment	5 years

Countries

Norway

Outcome results

None listed